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Reasons for using pharmacological stress as a substitute for physical exercise may vary. In the nuclear cardiology laboratory, patients generally perform physical exercise on treadmill or bicycle. Pharmacological stress is used in selected patients who are incapable of performing adequate physical exercise because of orthopedic, neurologic, peripheral vascular, or other medical problems.1 On the other hand, in the echocardiography laboratory, the performance of physical exercise in conjunction with two-dimensional echocardiography is a challenging task, and an alternative mode of nonphysical stress may be preferred in most patients.2.3
The first pharmaceutical to be employed for simulating cardiac stress was intravenously administered dipyridamole.4 Dipyridamole has been used in combination with Tl scintigraphy for more than a decade. Recently, new agents for pharmacological stress have been introduced -adenosines and dobutamine.6,7
The technology of radionuclide imaging and echocardiography has evolved considerably in recent years. Although planar radionuclide imaging remains an adequate imaging modality, single-photon emission computerized tomography (SPECT), which enables more precise detection of disease in specific coronary arteries, is now used widely. The new 9'9Tc-labeled imaging agents, such as Sestamibi, now ensure consistently goodquality SPECT images. 8, 9 Similar to radionuclide images, echocardiographic images are now often acquired on dedicated minicomputers. Selected formed in conjunction with either intravenous infusion of high-dose dipyridamole or dobutamine.7,10,11
At the present time, it is not clear which pharmacological stress is best suited for which imaging modality. Therefore, the report by Marwick et al in this issue of Circulation12 is of considerable interest and of importance for the disciplines of nuclear cardiology and echocardiography. The investigators evaluated prospectively in a consecutive series of 97 patients the diagnostic yield of adenosine and dobutamine stress in conjunction with 9'Tc-Sestamibi SPECT and digitized two-dimensional echocardiography. This study is unique since each patient underwent four different stress test combinations.
The results and conclusions of this study are important and helpful for clinical practice. Adenosine SPECT-MIBI appeared to be a sensitive method (sensitivity, 86%), comparable to that of dobutamine twodimensional echocardiography (85%) and dobutamine SPECT-MIBI (80%). However, these three combinations were substantially superior compared with adenosine two-dimensional echocardiography, which had a sensitivity of only 58%.
In view of the different mechanisms of action of adenosine and dobutamine, these results should not be surprising.
Intravenous infusion of adenosine causes near-maximal dilatation of the coronary resistance vasculature and near-complete recruitment of the coronary blood flow reserve. In patients with significant coronary artery disease, this results in marked heterogeneity of regional myocardial blood flow. Blood flow in regions supplied by normal coronary arteries increases to a greater extent than in regions supplied by arteries with significant stenoses. This heterogeneity of regional myocardial blood flow can be imaged with radioactive myocardial perfusion imaging agents as an area with relatively diminished uptake of radiotracer. In most patients, no myocardial ischemia is created, and therefore regional wall motion remains normal. This explains the relatively low sensitivity of adenosine two-dimensional echocardiography in Marwick et al's study.
In contrast, the primary effect of dobutamine infusion constitutes an increase in heart rate and systolic blood pressure and thus a direct increase in myocardial oxygen demand, similar to that occurring during moderate physical exercise. To accommodate the increased metabolic demand, regional nutrient myocardial blood flow must increase accordingly. In the presence of a significant coronary stenosis, insufficient increase in regional myocardial blood flow leads to ischemia and abnormal regional wall motion. Thus, both adenosine and dobu-tamine create heterogeneity of myocardial blood flow. The heterogeneity is probably more pronounced with adenosine than with dobutamine. With dobutamine, this heterogeneity is almost always associated with ischemic wall motion abnormality, whereas this is not necessarily the case with adenosine.
It should be noted that in Marwick et al's study the administered doses of both pharmacological stresses were relatively high compared with those commonly used in clinical practice (180 1g/kg/min for adenosine and 40 gg/kg/min for dobutamine). Therefore, both tests were evaluated at their full potential. In this regard, it is relevant to examine the clinical feasibility of reaching an adequate end point with both modalities. Infusion of the pharmaceutical had to be stopped prematurely in 36% of patients using dobutamine and in 28% of patients using dipyridamole. With dobutamine, the test was most often terminated by the physician, e.g., because of marked change in blood pressure, while the patient was asymptomatic. On the other hand, with adenosine it was frequently the patient who complained about side effects, necessitating premature termination of infusion. The majority of the patients whose test was terminated prematurely had positive tests and therefore sensitivity was most likely not significantly affected. The percentage of patients with nondiagnostic tests, i.e., negative results and premature termination of infusion, was 12% for dobutamine and 18% for adenosine. It is in the latter group of patients that coronary artery disease might have been missed. Therefore, although side effects were relatively frequent with both agents, the prevalence of potentially false-negative tests was acceptable. From a practical point of view, both adenosine and dobutamine have a rapid onset of action and a short plasma half-life -30 and 120 seconds, respectively. Thus, adverse side effects usually can be easily controlled by stopping the infusion.
It is important to note that Marwick et al intentionally excluded patients with prior myocardial infarction. The focus was on the detection of stress-induced ischemia (transient changes in myocardial perfusion or regional wall motion) rather than on identification of coronary artery disease. It 
